Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma
- 11 January 2016
- journal article
- research article
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 30 (3) , 234-241
Abstract
The aim of our study was to determine the role of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) and indium-111 Octreotide single photon emission tomography (111In-Octreotide SPECT) in the evaluation of metastatic medullary thyroid carcinoma (MMTC).Keywords
This publication has 34 references indexed in Scilit:
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid CarcinomaThyroid®, 2015
- Current Update on Medullary Thyroid CarcinomaAmerican Journal of Roentgenology, 2013
- Current Understanding and Management of Medullary Thyroid CancerThe Oncologist, 2013
- Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysisEndocrine, 2012
- Advances in the follow-up of differentiated or medullary thyroid cancerNature Reviews Endocrinology, 2012
- 2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid CancerEuropean Thyroid Journal, 2012
- 18F‐FDG‐PET and 18F‐FDG‐PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: A systematic review and meta‐analysisJournal of Medical Imaging and Radiation Oncology, 2012
- Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling timesEuropean Journal of Endocrinology, 2008
- New therapeutic approaches to treat medullary thyroid carcinomaNature Clinical Practice Endocrinology & Metabolism, 2008
- Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin LevelsThe Journal of Clinical Endocrinology & Metabolism, 2007